Curis (CRIS) Trading Up 5.3%
Curis, Inc. (NASDAQ:CRIS) traded up 5.3% on Tuesday . The company traded as high as $2.37 and last traded at $2.17. 712,636 shares were traded during mid-day trading, an increase of 94% from the average session volume of 367,861 shares. The stock had previously closed at $2.06.
A number of equities research analysts have weighed in on the company. Cowen reiterated a “buy” rating on shares of Curis in a research note on Tuesday, September 25th. Zacks Investment Research lowered Curis from a “buy” rating to a “hold” rating in a report on Monday, August 13th. SunTrust Banks dropped their target price on Curis to $8.00 and set a “buy” rating on the stock in a report on Friday, August 3rd. Finally, ValuEngine lowered Curis from a “buy” rating to a “hold” rating in a report on Monday, July 2nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Curis presently has a consensus rating of “Buy” and a consensus target price of $18.75.
The firm has a market cap of $59.06 million, a PE ratio of -1.24 and a beta of 1.11. The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 4.43.
Several large investors have recently added to or reduced their stakes in the company. LMR Partners LLP acquired a new position in Curis during the second quarter worth $124,000. Paloma Partners Management Co acquired a new position in Curis during the second quarter worth $223,000. Finally, Millennium Management LLC acquired a new position in Curis during the second quarter worth $540,000. 33.49% of the stock is currently owned by institutional investors and hedge funds.
Curis Company Profile (NASDAQ:CRIS)
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Recommended Story: What are earnings reports?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.